Ultra large docking reveals novel chemotypes and a distinct binding mode for Porcupine inhibition
Wnt signaling is essential for embryonic development and adult tissue homeostasis, and its dysregulation contributes to cancer and other human diseases. Porcupine (PORCN), a membrane-bound O-acyltransferase (MBOAT) required for Wnt palmitoylation and secretion, has emerged as an important therapeutic target. Despite promising preclinical results, PORCN inhibitors have shown limited clinical activity to date, motivating the search for new chemotypes and binding modes. Here, we docked a library of 1.3 billion molecules against PORCN and identified 16 novel compounds that inhibit Wnt signaling. These hits are structurally distinct from known PORCN inhibitors, and structure-based optimization of one series yielded sub-micromolar leads. Cryo-electron microscopy revealed that the lead inhibitor binds PORCN in an unreported mode within the palmitoleoyl-CoA chamber, positioned closer to the cytosol than existing inhibitors. Together, our findings expand the chemical and structural space available for targeting PORCN and provide new starting points for development of Wnt signaling antagonists.
Authors
- Yurii S. Moroz (ORCID: https://orcid.org/0000-0001-6073-002X)
- Boyuan Wang (ORCID: https://orcid.org/0000-0003-1854-6178)
- Dmytro S. Radchenko (ORCID: https://orcid.org/0000-0001-5444-7754)
- Qinli Hu (ORCID: https://orcid.org/0000-0001-6706-7347)
- Xiaochun Li (ORCID: https://orcid.org/0000-0002-0177-0803)
- Jie Li (ORCID: https://orcid.org/0000-0001-9085-6619)
- Fangyu Liu (ORCID: https://orcid.org/0000-0001-5022-0106)
- Jonathan Coria
- Chang Min Kim
- Hongying Cheng
Institutions
- DigitalSpace (United States) (US)
- Enamine (Ukraine) (UA)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Communications Biology
- Published
- 2026-10-30
- DOI
- https://doi.org/10.1038/s42003-026-11215-7
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Damon Runyon Cancer Research Foundation
- Cancer Prevention and Research Institute of Texas